NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT01989052 2016-08-04Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent GliomaDuke UniversityPhase 1 Terminated9 enrolled